The Lynx Group

Consolidation Therapy After ASCT in Hodgkin Lymphoma: Why and Who to Treat

The combined use of effective multidrug chemotherapy regimens and radiation over the past few decades has led to significant improvements in the prognosis of Hodgkin lymphoma, making achievement of a cure a clinical reality for the majority of patients.1 With current therapies, long-term tumor control may be achieved in 70%-80% of patients.1 However, a subset of patients do not respond to frontline therapy or relapses following initial response.
Read Article

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: